GB0814340D0 - Anhydrous crystol form fo a pyridine derivative - Google Patents

Anhydrous crystol form fo a pyridine derivative

Info

Publication number
GB0814340D0
GB0814340D0 GBGB0814340.6A GB0814340A GB0814340D0 GB 0814340 D0 GB0814340 D0 GB 0814340D0 GB 0814340 A GB0814340 A GB 0814340A GB 0814340 D0 GB0814340 D0 GB 0814340D0
Authority
GB
United Kingdom
Prior art keywords
crystol
anhydrous
pyridine derivative
pyridine
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0814340.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerre Therapeutics Ltd
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to GBGB0814340.6A priority Critical patent/GB0814340D0/en
Publication of GB0814340D0 publication Critical patent/GB0814340D0/en
Priority to JP2011521561A priority patent/JP2011529942A/ja
Priority to BRPI0917224A priority patent/BRPI0917224A2/pt
Priority to PCT/EP2009/060089 priority patent/WO2010015626A1/en
Priority to EP09781468A priority patent/EP2321324A1/en
Priority to EA201170300A priority patent/EA201170300A1/ru
Priority to CN2009801393221A priority patent/CN102171219A/zh
Priority to MX2011001414A priority patent/MX2011001414A/es
Priority to KR1020117005159A priority patent/KR20110052686A/ko
Priority to AU2009279135A priority patent/AU2009279135B2/en
Priority to CA2733235A priority patent/CA2733235A1/en
Priority to US13/056,775 priority patent/US8093242B2/en
Priority to ZA2011/00426A priority patent/ZA201100426B/en
Priority to IL210777A priority patent/IL210777A0/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB0814340.6A 2008-08-05 2008-08-05 Anhydrous crystol form fo a pyridine derivative Ceased GB0814340D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB0814340.6A GB0814340D0 (en) 2008-08-05 2008-08-05 Anhydrous crystol form fo a pyridine derivative
US13/056,775 US8093242B2 (en) 2008-08-05 2009-08-04 Crystalline forms of a pyridine derivative
CN2009801393221A CN102171219A (zh) 2008-08-05 2009-08-04 吡啶衍生物的晶型
KR1020117005159A KR20110052686A (ko) 2008-08-05 2009-08-04 피리딘 유도체의 결정질 형태
PCT/EP2009/060089 WO2010015626A1 (en) 2008-08-05 2009-08-04 Crystalline forms of a pyridine derivative
EP09781468A EP2321324A1 (en) 2008-08-05 2009-08-04 Crystalline forms of a pyridine derivative
EA201170300A EA201170300A1 (ru) 2008-08-05 2009-08-04 Кристаллические формы пиридинового производного
JP2011521561A JP2011529942A (ja) 2008-08-05 2009-08-04 ピリジン誘導体の結晶体
MX2011001414A MX2011001414A (es) 2008-08-05 2009-08-04 Formas cristalinas de un derivado de piridina.
BRPI0917224A BRPI0917224A2 (pt) 2008-08-05 2009-08-04 formas cristalinas de um derivado de piridina
AU2009279135A AU2009279135B2 (en) 2008-08-05 2009-08-04 Crystalline forms of a pyridine derivative
CA2733235A CA2733235A1 (en) 2008-08-05 2009-08-04 Crystalline forms of a pyridine derivative
ZA2011/00426A ZA201100426B (en) 2008-08-05 2011-01-17 Crystalline forms of a pyridine derivative
IL210777A IL210777A0 (en) 2008-08-05 2011-01-20 Crystalline forms of a pyridine derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0814340.6A GB0814340D0 (en) 2008-08-05 2008-08-05 Anhydrous crystol form fo a pyridine derivative

Publications (1)

Publication Number Publication Date
GB0814340D0 true GB0814340D0 (en) 2008-09-10

Family

ID=39767571

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0814340.6A Ceased GB0814340D0 (en) 2008-08-05 2008-08-05 Anhydrous crystol form fo a pyridine derivative

Country Status (14)

Country Link
US (1) US8093242B2 (https=)
EP (1) EP2321324A1 (https=)
JP (1) JP2011529942A (https=)
KR (1) KR20110052686A (https=)
CN (1) CN102171219A (https=)
AU (1) AU2009279135B2 (https=)
BR (1) BRPI0917224A2 (https=)
CA (1) CA2733235A1 (https=)
EA (1) EA201170300A1 (https=)
GB (1) GB0814340D0 (https=)
IL (1) IL210777A0 (https=)
MX (1) MX2011001414A (https=)
WO (1) WO2010015626A1 (https=)
ZA (1) ZA201100426B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102639536B (zh) * 2009-08-27 2015-03-18 尼尔医疗有限公司 吡啶衍生物的无水晶型
EP3574907B1 (en) * 2015-05-18 2023-08-23 KaNDy Therapeutics Limited A dual nk-1/nk-3 receptor antagonist for the treatment of sex-hormone-dependent diseases
JP7433252B2 (ja) 2018-03-14 2024-02-19 キャンディ・セラピューティクス・リミテッド Ｎｋ－１／ｎｋ－３受容体二重アンタゴニストを含む新規な医薬製剤
KR102950227B1 (ko) 2019-11-15 2026-04-08 칸디 테라퓨틱스 리미티드 Nt-814의 핵심 중간체인 6-클로로-4-(4-플루오로-2-메틸페닐)피리딘-3-아민의 새로운 화학적 제조 방법
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE265209T1 (de) 1996-07-17 2004-05-15 Merck & Co Inc Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
EP1394150B1 (en) * 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
WO2001030348A1 (en) 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
SI1643998T1 (sl) * 2003-07-03 2007-12-31 Hoffmann La Roche Dvojni nk1/nk3 antagonisti za zdravljenje shizofrenije
EP1928886B1 (en) * 2005-09-09 2011-04-13 GlaxoSmithKline LLC Pyridine derivatives and their use in the treatment of psychotic disorders

Also Published As

Publication number Publication date
US20110136798A1 (en) 2011-06-09
CA2733235A1 (en) 2010-02-11
BRPI0917224A2 (pt) 2015-11-24
EP2321324A1 (en) 2011-05-18
MX2011001414A (es) 2011-04-04
ZA201100426B (en) 2012-03-28
US8093242B2 (en) 2012-01-10
JP2011529942A (ja) 2011-12-15
IL210777A0 (en) 2011-03-31
WO2010015626A1 (en) 2010-02-11
CN102171219A (zh) 2011-08-31
AU2009279135A1 (en) 2010-02-11
EA201170300A1 (ru) 2011-08-30
AU2009279135B2 (en) 2012-09-13
KR20110052686A (ko) 2011-05-18

Similar Documents

Publication Publication Date Title
IL209727A0 (en) Pyridine compounds
ZA201105479B (en) Pyridine derivative
IL212536A0 (en) Substituted pyridines having a herbicidal effect
IL206276A0 (en) Pyridine derivatives
GB0916768D0 (en) A door closer
PT2336132E (pt) Derivado de morfolinopurina
EP2269993A4 (en) 2-aminoquinazoline DERIVATIVE
IL206875A0 (en) Bicycloamine derivative
IL208623A0 (en) Cyclopentylacrylamide derivative
EP2340752A4 (en) TOASTER
GB0908606D0 (en) A stereo-endoscope
IL213466A0 (en) Spiroindolinone pyridine derivative
IL205666A0 (en) Pyridine compounds
GB0814340D0 (en) Anhydrous crystol form fo a pyridine derivative
ZA201007615B (en) Aminopyridine derivatives
ZA201006992B (en) Hydroxyquinoxalinecarboxamide derivative
GB0922260D0 (en) A pipe-liner
IL191243A0 (en) A connector profile unit for panels
IL214028A0 (en) A novel cyanopyrimidine derivative
IL212683A0 (en) Biphenylacetamide derivative
GB2457509B (en) A freezer
GB2458284B (en) A button-cuff
GB2453396B (en) A Time piece
PL2331889T3 (pl) Lodówka
GB0915533D0 (en) A door

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
COOA Change in applicant's name or ownership of the application

Owner name: NERRE THERAPEUTICS LIMITED

Free format text: FORMER OWNER: SMITHKLINE BEECHAM CORPORATION